Combe Bernard, Behrens Frank, McHugh Neil, Brock Fiona, Kerkmann Urs, Kola Blerina, Gallo Gaia
From the Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University, Montpellier, France; CIRI/Rheumatology, Goethe-University and Fraunhofer IME, Translational Medicine and Pharmacology, Frankfurt am Main, Germany; Royal National Hospital for Rheumatic Diseases and Department of Pharmacy and Pharmacology, University of Bath, Bath; Statistical Consultancy, Quanticate, Hitchin; Pfizer United Kingdom, Tadworth, UK; Pfizer Europe, Rome, Italy.B. Combe, MD, Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University; F. Behrens, MD, CIRI/Rheumatology, Goethe-University and Fraunhofer IME, Translational Medicine and Pharmacology; N. McHugh, MD, Royal National Hospital for Rheumatic Diseases and Department of Pharmacy and Pharmacology, University of Bath; F. Brock, MSc, Statistical Consultancy, Quanticate; U. Kerkmann, MD, former employee of Pfizer Europe; B. Kola, MD, Pfizer United Kingdom; G. Gallo, MD, Pfizer Europe.
J Rheumatol. 2016 Jun;43(6):1063-7. doi: 10.3899/jrheum.151290. Epub 2016 May 1.
To evaluate the clinical/functional outcomes associated with etanercept (ETN) monotherapy versus combination therapy in psoriatic arthritis (PsA).
Data from patients with PsA who received ETN alone (n = 322) or combined with methotrexate (MTX; n = 152) for 24 weeks in 2 placebo-controlled clinical trials were summarized across studies.
Similar proportions of patients in the monotherapy and combination therapy groups achieved the PsA Response Criteria (80% and 83%) and the American College of Rheumatology improvements of 20% (ACR20; both 70%); numerically higher proportions receiving monotherapy achieved ACR50 (55% vs 48%) and ACR70 (35% vs 27%). Little between-group difference was observed in the 28-joint Disease Activity Score with C-reactive protein, the Psoriasis Area and Severity Index, and the Health Assessment Questionnaire-Disability Index improvement.
ETN with and without MTX provided similar benefits in active PsA.
评估依那西普（ETN）单药治疗与联合治疗在银屑病关节炎（PsA）中的临床/功能结局。
汇总两项安慰剂对照临床试验中接受ETN单药治疗（n = 322）或联合甲氨蝶呤（MTX；n = 152）治疗24周的PsA患者的数据。
单药治疗组和联合治疗组中达到PsA反应标准（分别为80%和83%）以及美国风湿病学会20%改善标准（ACR20；均为70%）的患者比例相似；接受单药治疗的患者在达到ACR50（55%对48%）和ACR70（35%对27%）方面的数值比例更高。在28关节疾病活动评分（含C反应蛋白）、银屑病面积和严重程度指数以及健康评估问卷残疾指数改善方面，组间差异不大。
无论是否联合MTX，ETN在活动性PsA中均提供相似的益处。
